Interestingly, in the first-line A + I + chemo group, stratification analysis using PD-L1 expression showed comparable PFS across all categories of tumor PD-L1 expression levels (<1%, 1%–49%, and >50%; median 10.1, 8.6, and 10.9 months), which were better than those in the control arm (median 7.6, 7.2, and 6.9 months). The gene discussed is CD274; the disease is neoplasm.